Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will mark a significant corporate milestone by ringing the opening bell at the Nasdaq Stock Market on Monday, May 12, 2025, in …
Palvella Therapeutics to Ring Nasdaq Opening Bell Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that an abstract presenting groundbreaking data on the prevalence and annual incidence of lymphatic malformations (LMs) in the U.S. has been …
Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORIN™ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare …
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations (microcystic LMs) at the 15th World …
Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that its Founder and Chief Executive Officer, Wes Kaupinen, will take part in a fireside chat at the Jones Healthcare …
Palvella CEO to Present at Healthcare Innovation Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will take center stage at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina, with a late-breaking oral presentation on …
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA), a biopharmaceutical company focused on developing treatments for rare genetic skin diseases, has announced its financial results for 2024, alongside key corporate and …
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that its management team will deliver a presentation at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled …
Palvella Therapeutics to Present at TD Cowen 45th Annual Healthcare Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), to include children as young …
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations …
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease Read More